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Abstract
We examined the link between gestational biomarkers and breast cancer in 9169 daughters born 
into the Child Health and Development Studies from 1959 to 1967. We identified 137 breast 
cancer cases diagnosed by age 52 as of 2012. Markers of increased risk included higher placental 
volume and rapid 2nd trimester gestational weight gain. Protective markers were placental 
hemorrhage and fibrin deposition, indicators of resistance to placental trophoblast invasion. 
Paradoxically, higher ponderal index at birth was protective suggesting that fetal and placental 
pathways to breast cancer are multiple and distinct. Results link placental and fetal phenotypes to 
breast cancer, characterizing some as restrictive and others as permissive markers of tumor 
development. We found new biomarkers of breast cancer risk that can be mined to discover ‘omic 
correlates in the pregnancy exposome using archived and contemporary pregnancy samples. This 
line of investigation may discover new pathways to risk and new opportunities for prevention.
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1. Introduction
Animal and human studies have demonstrated that certain placental phenotypes are related 
to subsequent risk of cancer [1–5]. The theoretical basis of this link between the feto-
placental unit and cancer later in life emerges from a growing science that has revealed how 
conspicuously the trophoblast cells of the human placenta mimic those of malignant tumor 
cells – both exhibit properties of proliferation, migration and invasion [1,6]. However, 
human placental cells are generally bestowed with the ability to arrest these processes and 
finally assume a state of senescent apoptosis [6]. The placenta mobilizes nutrients to the 
fetus and screens toxins, organizes an immune balance with the fetal allograft and performs 
major endocrine functions. Impairment of these placental roles has the potential to lead to 
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disordered developmental programming and alterations in the structure and function of 
major fetal organ systems through modification of gene expression or cell differentiation, 
which predispose offspring to disease [1,6].
The concept that the intrauterine environment plays a major role in establishing a growth 
and health trajectory that extends over the life-course of the offspring is widely supported by 
numerous studies [7–9]. Combining this concept with the rapidly increasing insight about 
the similarities between placenta trophoblast cells and tumor cells [1,6] forms the basis for 
our investigation of the link between the placenta, fetal growth and later life risk of breast 
cancer.
Previously we observed that clinical characteristics during pregnancy and placental 
morphology were associated with the mother’s own subsequent risk of breast cancer. In 
brief, we found that smaller placentas, presence of maternal floor infarction of the placenta 
and more rapid blood pressure change between the 2nd and 3rd trimesters were associated 
with significant reduction in risk of maternal breast cancer, later in life [10]. The current 
study examines whether these factors are associated with risk of breast cancer in daughters. 
We also expand our search for daughters’ breast cancer risk factors to include additional 
measures of placenta function and fetal growth which have been extensively implicated in 
the development of subsequent chronic disease [1,7,9,11].
2. Materials and methods
2.1. Study population
This study is based on the Child Health and Development Studies, a population-based, 
multi-generational cohort. The CHDS recruited more than 98% of women seeking obstetric 
care at the Kaiser Foundation Health Plan in the San Francisco East Bay Area from 1959 to 
1967 [12]. Recruitment efforts enrolled 15,528 families into the cohort which is racially and 
ethnically diverse with a broad socio-economic base and uniform access to health care. 
Demographics and health-related behavior were collected from mothers during in-person 
interviews at enrollment, early in the first trimester. Clinical measures were abstracted from 
maternal medical records beginning 6 months prior to pregnancy through labor and delivery 
and are the source of data on baseline pregnancy weight, gestational weight gain, blood 
pressure change, length of gestation and birthweight. A standardized gross placental exam 
was conducted at delivery by trained examiners using the Benirschke protocol [13]. Delivery 
room nurses refrigerated the placentas, the preferred method of preservation for macroscopic 
exam, and an examiner was notified as soon as possible. Placental exams were usually 
completed within a few hours of delivery, except for late-night and Sunday births which 
were conducted within 12-24 hours of delivery. These exams were routinely performed for 
95% of births during time periods when funding was available: August, 1960 – December, 
1963 and October, 1965 – August, 1966. Thus availability of placental data for all CHDS 
births ranges from 56% to 78%, depending on the characteristic. For example placental 
weight is more widely available, for 78% of all births, whereas placental volume (which 
requires measurement of all three dimensions of the placenta – large diameter, small 
diameter, and thickness) is less frequently available, for nearly 60% of all births.
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2.2. Cohort surveillance
Surveillance of CHDS participants has continued for 6 decades by annual linkage to: 1) the 
California Department of Motor Vehicles for a history of residence to identify the population 
at risk for cancer, 2) the California Department of Vital Statistics, for identifying deaths and 
cause [14–16] and 3) the California Cancer Registry, for identifying cancer diagnoses 
[10,17–21]. CHDS mothers and their families are regularly matched to these sources using 
an accumulated name and address history. This cumulative history protects against 
establishing false matches and failing to identify true matches. Surveillance efforts routinely 
identify over 80% of CHDS families.
Breast cancer cases in CHDS daughters were identified by linkage to the California Cancer 
Registry (CCR) and by self-report during a computer-assisted telephone interview in an 
adult follow-up study of CHDS daughters from 2010 to 2013. California hospitals and health 
care facilities that provide treatment to cancer patients are required by law to report cancer 
diagnoses to the California Cancer Registry. The CCR has established that its cancer 
coverage is more than 99% complete after a lag time of about 2 years [23]. Life table 
analyses using SEER rates to estimate expected numbers of breast cancer diagnoses in 
mothers (unpublished) and testicular cancer diagnoses in sons [19] in the CHDS show close 
comparability with observed cases identified through CCR linkage in both parent and 
offspring generations.
We identified 137 cases of incident invasive or in situ breast cancer cases in CHDS 
daughters via linkage to the CCR through 2012 (80% of cases) and direct self-report through 
2013 (20% of cases). The self-reported cases were more recently diagnosed and most fell 
within the 2-year lag period required for CCR to completely capture these later diagnoses. 
Tumor stage and hormone receptor status were available from CCR records which abstracts 
information from pathology reports and medical records about timing of diagnosis, cancer 
site, tumor invasiveness, histology, grade and differentiation, and tumor biomarkers [22]. 
Cases were diagnosed from 1992-2012 at ages 32–52 years.
The institutional review board of the Public Health Institute approved the study protocols for 
this research. At enrollment CHDS mothers gave informed oral consent, as was customary in 
the 1960’s, for themselves and their children. Daughters who provided self-report of their 
breast cancer diagnoses from 2010-2013 gave full informed verbal consent before 
participating in the adult telephone survey.
2.3. Statistical methods
Main study variables comprised measures of fetal growth and development, prenatal 
conditions and characteristics of the placenta which are described as follows. Birthweight-
for-gestation z-scores were calculated for female CHDS births by subtracting the individual 
birthweight from the mean for each gestational week and dividing the difference by the 
standard deviation of the mean. Scores below the 10th percentile of the birthweight-for-
gestation distribution were used to identify small for gestational age (SGA) births vs. all 
other z-scores at or above the 10th percentile. Ponderal index was calculated as [birthweight 
(g) / birth length (cm3)] x 100 and represented as a 4-category ordinal variable where 
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categories were assigned the median value of each quartile. The rates of maternal gestational 
weight gain were calculated separately for trimester 2 and trimester 3 as: [(the last recorded 
maternal weight (lbs.) in each trimester – the first recorded maternal weight (lbs.) in each 
trimester) / (gestational days between dates of the first and last measurements in each 
trimester)]. Dose-response for rates of weight gain in each trimester was tested using 3 
dummy variables representing quartile 2, quartile 3 and quartile 4, using the first as the 
reference quartile. Because risk for 2nd trimester rate of weight gain was concentrated in the 
highest quartile, trimester-specific rates of weight gain were thereafter classified as the 
highest quartile (quartile 4) versus all others, where the highest quartile of trimester 2 
equated to a rate of weight gain ≥1.17 pounds per week and the highest quartile of trimester 
3 was equivalent to a rate of gain ≥0.99 pounds per week [24]. Placental volume (cm3) 
encompassed three dimensions – the largest diameter (cm) of the placenta, the smallest 
diameter (cm) and its thickness (cm). It was calculated based on the formula for the volume 
of an ellipse: 4/3 × 3.14 X [large diameter/2] X [small diameter/2] X [thickness/2]. Fibrin 
deposition was defined as the presence of maternal floor infarction of the placenta and/or 
massive or diffuse and patchy subchorionic fibrin. Evidence of hemorrhage in the placenta, 
recent or old, without designation of specific site; presence of placental cysts; and presence 
of placental tumor (reportedly benign chorioangioma [13]) were each captured as binary 
variables (1 = observed and 0 = not observed).
Adjustment variables included maternal and offspring variables and are outlined as follows. 
Maternal ancestry was determined from in-person interview at enrollment and was 
characterized as Eastern European, a proxy for Ashkenazi Jewish heritage vs. all other. 
Maternal baseline pregnancy overweight was defined as having a body mass index of ≥25 
kg/m2. Body mass index was calculated from weight (kg) divided by height (m) squared, 
measured or reported at interview or first prenatal visit. Weight was adjusted to compensate 
for variation in the timing of measurement by regressing weight on gestational age using the 
locally weighted scatterplot smoothing technique [25]. Adjusted weight was then imputed as 
the fitted mean weight at day 104 of gestation (median value for day of interview) plus the 
residual from the regression procedure. Gestational age was calculated as the time in 
completed weeks between date of delivery and date of last menstrual period. Maternal 
history of breast cancer was captured from maternal record linkage to the California Cancer 
Registry. Daughter year of birth was taken directly from labor and delivery records. Other 
maternal variables that were considered included: age at pregnancy (continuous), parity at 
pregnancy (continuous and dichotomized as primiparous vs. all other), maternal education 
(using two indicator variables for high school and some college vs. less than high school as 
the reference group), and total family income (using two indicator variables for at the 
median income adjusted for 1960 dollars and above the median vs. below the median as the 
reference group).
Daughter breast cancer incidence rates and 95% confidence intervals were calculated based 
on the discrete probability distribution for a binomial parameter. Hazard ratios were 
estimated using Cox proportional hazards models with the robust sandwich estimate option 
to account for family clusters since there were some sisters in the cohort [26]. Age at breast 
cancer diagnosis or follow-up was used as the censoring variable for these models. Since all 
cohort members are regularly monitored for residence, cancer and vital status, we used year 
Cirillo and Cohn Page 4
Reprod Toxicol. Author manuscript; available in PMC 2020 November 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
of last contact from all sources and from telephone contact during follow-up studies, to 
create the age at censorship. It was calculated by subtracting the year of diagnosis or 
censorship (last year of contact) from the year of birth, and ranged from 6 months to 52 ½ 
years from birth. Main study variables were tested in univariate models which included only 
the study variable of interest, then in models which included the main variable and the 
adjustment variables (maternal race, maternal baseline overweight, gestational age, maternal 
history of breast cancer and offspring year of birth) and finally in the fully adjusted model. 
The fully adjusted study model simultaneously estimated all main study variable 
associations and included the adjustment variables. Due to high collinearity, ponderal index 
and SGA were not both included in the fully adjusted model. To estimate the adjusted breast 
cancer association with ponderal index, SGA was omitted from the fully adjusted model, 
and to estimate the adjusted effect for SGA, ponderal index was omitted.
To investigate the effects of sample attrition due to missing on study variables, we used 
multiple imputation to estimate associations. Multiple imputation was implemented in 
SAS9.4 using the fully conditional algorithm (FCS) so that it could be applied to 
proportional hazards regression [27]. Estimates were based on 20 iterative imputations.
2.4. Analysis sample
The present analysis is based on the 9169 live-born CHDS daughters who were followed for 
nearly 6 decades from birth and among whom we identified 137 cases of breast age through 
age 52. To ensure greater accuracy for the macroscopic placental exam we restricted analysis 
to births from 32 – 44 gestational weeks, excluding 418 observations. From the remaining 
observations, information required to calculate a standardized birthweight z-score and 
ponderal index was available for n = 8570 daughters including 127 cases. Among these, 
information on all adjustment variables (maternal race, maternal baseline overweight, 
gestational age and maternal history of breast cancer) was available for n = 7,534, including 
109 cases. Additionally requiring prenatal measures in both 2nd and 3rd trimesters resulted 
in n = 5228 observations including 74 cases. And finally, requiring all placental measures 
yielded a final sample size of 2947 observations, including 44 offspring breast cancers.
3. Results
We identified 137 cases of young breast cancer among CHDS daughters. Cases were 
diagnosed between ages 32-52 years occurring from 1992 to 2012. The median age at 
diagnosis was between 43-44 years.
Unadjusted breast cancer incidence rates of daughter breast cancer reported in Table 1 
support modeled results of breast cancer associations for study variables, provided in Table 2 
and Fig. 1. All show that increased ponderal index is associated with decreased breast cancer 
risk in daughters, while small for gestational age is associated with increased risk. Rapid 
maternal weight gain in the 2nd trimester (4th quartile of weight gain rate), but not in the 
3rd, predicted increased risk of breast cancer in daughters. Consistent with higher risk 
associated with rapid weight gain in the 2nd trimester, higher placental volume (greater than 
median) was also associated with higher risk that was marginally statistically significant, 
whereas the presence of fibrin deposition and indication of placental hemorrhage were 
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associated with lower risk. Although fibrin deposition and hemorrhage can occur in concert, 
most were unique events: 70% of fibrin deposition occurred in the absence of hemorrhage 
and conversely 85% of hemorrhage occurred in the absence of fibrin deposition. We also 
observed that the presence of placental tumor was associated with very high increased risk 
of daughter’s breast cancer that was statistically significant; however, due to small numbers 
we consider this suggestive evidence that needs to be corroborated.
Table 2 presents associations of gestational variables with daughter breast cancer for 
increasing levels of adjustment and missingness due to sample attrition. Associations were 
not largely affected by adjustment for maternal variables. Table 2 also shows that 
associations are independent of one another and not explained by familial risk. Sensitivity 
analysis (data not shown) demonstrated that sample attrition had comparatively little impact 
on the associations and do not materially alter conclusions. Associations based on multiple 
imputation (Supplementary Table 1) were also highly comparable to those reported in Table 
2, suggesting that sample attrition did not largely influence results. The primary impact of 
imputation was to slightly diminish the magnitude of associations and increase p-values; 
however, the direction and interpretation of results are not substantially altered from 
conclusions based on results in the smaller non-missing sample. In addition, rates of breast 
cancer were highly similar for daughters included in the fully adjusted model compared to 
daughters who were excluded due to one or more missing variables, incidence rates and 95% 
confidence intervals were: 4.21 per 10,000 (3.06 to 5.65) among daughters included in the 
fully adjusted model vs. 4.29 per 10,000 (3.46 to 5.25) among daughters not included.
Fig. 1 depicts breast cancer associations for placental and fetal markers as well as for 
selected maternal co-variables. Both maternal history of breast cancer and maternal East 
European ancestry were substantial predictors of daughter’s breast cancer. East European 
ancestry includes countries of origin with high proportions of Ashkenazi Jews, who have a 
high prevalence of deleterious mutations in the BRCA1 and BRCA2 genes [28], and may 
therefore be a proxy marker of genetic risk. Maternal baseline pregnancy overweight was 
associated with decreased risk of breast cancer in daughters. Other maternal adjustment 
variables, age at pregnancy, parity at pregnancy, and education and total family income at 
pregnancy did not affect reported associations and were not themselves related to offspring 
breast cancer (data not shown).
Supplementary Table 2 provides associations for each quartile of trimester-specific rates of 
maternal weight gain and for each quartile of ponderal index, estimated from models 
adjusted for maternal variables only; and, from fully adjusted models. Quartile-specific 
associations for maternal rates of weight gain show no evidence of a dose-response and 
further show that risk is concentrated in the 4th quartile, suggesting that a dichotomy 
representing the highest quartile vs. all others provides the best categorization for trimester 2 
and a homologous representation for trimester 3. Unlike rates of weight gain, the quartile-
specific associations for ponderal index exhibited a consistent step-down gradient supporting 
the putative classification of this measure as a 4-category ordinal variable with values coded 
at the median of each quartile.
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Supplementary Table 3 presents the results of a pilot study examining associations for early 
stage and for estrogen-receptor positive breast tumors. Tumors were predominantly 
diagnosed at an early stage (localized or in situ, 71%) and primarily identified as estrogen-
receptor positive (ER+, 83%) and progesterone-receptor positive (PR+, 77%). Associations 
reported in Supplementary Table 3 are highly comparable to those observed for all tumors. 
However, due to small numbers available for examining these re-classified outcomes, we 
consider the tumor stage and hormone receptor associations as pilot results. Not shown in 
Supplementary Table 3 are the associations for progesterone-receptor positive – these were 
highly similar to those for ER+ results since most ER+ tumors were also PR+.
4. Discussion
We tested the hypothesis that the intrauterine environment, as characterized by fetal 
measures and placental morphology, aligns with vulnerability to tumor development and/or 
progression and therefore can serve as biomarkers of breast cancer risk. This hypothesis 
integrates two prominent concepts: 1) the fetal origins of adult disease concept, which 
postulates that events during gestation, such as malnutrition, can affect fetal programming 
and lead to perturbations in the body’s structure, function and metabolism ultimately 
contributing to adult disease [9,29]; and, 2) the placental origins of disease concept based on 
the striking similarities between the placental trophoblast and malignant tumor cells [1,6]. 
Both concepts lead to the conclusion that the intrauterine environment plays a primary role 
in the determination of cancer susceptibility. Our results support this conclusion and provide 
evidence that both placental factors and fetal factors predict daughter breast cancer.
4.1. Placental factors
Gestational weight gain in the 2nd trimester reflects rapid placental growth and output of 
hormones that lead to increasing blood volume [30]. We observed an association of higher 
2nd trimester weight gain, but not 3rd trimester weight gain with increased risk of daughter 
breast cancer. Placental surface area, one component of volume is established by the 2nd 
trimester [1]. We found that placenta volume is also associated with increased risk of 
daughter breast cancer, further supporting the hypothesis that strong placental growth 
predicts a higher risk of daughter breast cancer. The observation that preeclampsia, a 
disorder of placentation with origins in early pregnancy [1], is associated with breast cancer 
protection in daughters [31] is further consistent with this hypothesis.
Other markers of placenta compromise, fibrin deposition and evidence of hemorrhage, were 
also associated with reduced risk of daughter breast cancer in this study. Fibrin deposition 
here includes the presence of subchorionic fibrin as well as report of maternal floor 
infarction. These are related placental lesions characterized by the marked fibrin deposition 
[32,33]. The etiology and full pathology of these lesions have yet to be elucidated but they 
are thought to result from an abnormal host-placenta interaction [32,33]. Angiongenic 
mechanisms may contribute to the association of these morphologic markers with breast 
cancer. In a small study, researchers found that angiogenic (P1GF) and anti-angiogenic 
(sVEGFR-1) factors and their ratio (PlGF/sVEGFR-1) were different for women who had 
massive perivillous fibrin deposition compared to those who did not [34].
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We also found that presence of placental tumor (described generally as chorioangioma) was 
associated with very high risk of breast cancer. Although this association was statistically 
significant, the small number of events requires caution and we were unable to characterize 
the histology of the tumors found. However, we include it here because its magnitude 
warrants follow-up in other samples, both animal and human.
4.2. Fetal factors
Controlling for placenta factors we found that fetal adiposity, approximated by higher 
ponderal index at birth, had a protective association with daughter breast cancer while SGA 
was associated with increased risk. The association of higher ponderal index with lower risk 
of daughter breast cancer by age 52 in the CHDS corresponds with recent findings from the 
Premenopausal Breast Cancer Collaborative Group [35]. They found that increased body 
mass index (BMI) is associated with a reduced risk of premenopausal breast cancer and this 
inverse risk was stronger at younger ages, beginning at age 18 years. Studies of BMI in 
adolescence and earlier, including in early childhood, also provide evidence for an inverse 
relationship of adiposity with premenopausal breast cancer [36–38]. Thus, it is not 
surprising to find that the protective association between adiposity and early breast cancer 
appears to begin at birth. We did not find an independent association of breast cancer with 
birthweight which has been reported in a number of prior studies [31].
Whether the protective association of ponderal index with daughter breast cancer derives 
from a nutrient-rich uterine environment that promotes fetal growth and the development of 
particular defense mechanisms remains to be determined. Interestingly, higher maternal 
adiposity (BMI > 25) was also protective of daughter breast cancer in our study, rendering 
plausible support to this possibility. Further, we observed that fetal growth retardation was 
associated with higher risk of breast cancer lending additional evidence that strong fetal 
growth may decrease vulnerability to premenopausal breast cancer.
Indicators of advantaged fetal growth and development were protective of daughter breast 
cancer as were specific markers of placental compromise. These observations are 
paradoxical and likely reflect different pathways to risk. Clearly the fetoplacental system 
requires the coordination of a massive, complex and redundant repertoire of functions to 
establish a balance that enables both fetal development and maternal well-being. Placental 
compromise associations may signify barriers to tumor invasion and proliferation or lower 
exposures to tumor initiators in fetal life, while fetal growth associations may indicate a 
sound and progressive developmental process resulting in organs with resilient structure and 
function. Why and how rapid gestational weight gain distinctly in the 2nd trimester predicts 
increased risk of daughter breast question is an important question that may focus the search 
for key mechanisms which promote tumor development.
4.3. Strengths and limitations
The CHDS is one of few large multi-generational cohort studies able to examine the 
relationship between the intrauterine environment and breast cancer incidence in a 
population-based sample. Even so, small sample size particularly in the full subset of all 
study variables resulted in large estimates of variance and associations which are subject to 
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random error. The univariate associations estimated in considerably larger subsets show 
close comparability with those estimated in the small subset, indicating that associations are 
not likely the result of sample attrition, or of small sample aberration. The analogous rates of 
breast cancer incidence among daughters who were included in the fully adjusted model 
(small subset) and daughters who were not also demonstrates that sample attrition due to 
missing information was not likely biased according to eventual breast cancer status. In 
addition, results based on multiple imputation methods to address effects of sample attrition 
(Supplementary Table 1) support conclusions drawn from the smaller non-missing sample.
It is possible that we failed to identify some cases of breast cancer. Through regular linkage 
to the California Cancer Registry, and vital status and DMV records, 70% of daughters were 
under continual surveillance from birth onward, with a median follow-up-time of > 45 years. 
However, about 30% were lost-to-follow-up within 10 years of birth, representing early lost-
to-follow-up and likely out-migration. Risk characteristics were represented proportionately 
according to early vs. continual surveillance status, i.e. daughters who were under continual 
surveillance did not over or under represent risk groups. This suggests that early loss was 
random and not biased according study characteristics; thus, we would expect that any 
missed cases would have the same distribution of risk characteristics as those observed for 
the study sample.
The standardization of the macroscopic placental exam performed by trained examiners 
ensured reliable accuracy for placental measures. The contemporaneous collection of 
prenatal, and labor and delivery information from obstetric records provided very high data 
quality. The pilot examination of tumor stage and hormone receptor status with placental and 
fetal characteristics produced associations that were highly similar to those observed for all 
tumors. This is not surprising since tumors were predominantly early stage and hormone-
receptor (estrogen and progesterone) positive. However, we were unable to determine 
whether early stage associations were different from late stage associations, nor whether 
hormone receptor positive were different from receptor negative effects since the small 
numbers of late stage and receptor negative tumors did not support separate examination. 
Thus, we are unable to draw conclusions about what role tumor invasiveness and receptor 
status play in the reported relationships.
5. Conclusions
We found that very rapid 2nd trimester gestational weight gain and higher placental volume 
predicted increased risk of daughter breast cancer. Consistent with this observation placental 
fibrin deposition and hemorrhage, all markers of placental compromise, predicted reduced 
risk. Fetal predictors did not align completely with placental predictors – higher ponderal 
index was protective for daughter breast cancer and fetal growth retardation was associated 
with increased risk – suggesting separate pathways to risk for fetal growth and placental 
function: These fetal and placental associations with breast cancer were independent of one 
another and were not explained by familial risk or maternal adiposity. Findings in this 
prospective study add strong support for the fetal and placental origins of disease 
hypotheses. We found new biomarkers of risk that can be mined to discover ‘omic correlates 
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in the pregnancy exposome using archived and contemporary pregnancy samples. This line 
of investigation may discover pathways to risk and new opportunities for prevention.
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Fig. 1. 
Associations of maternal and fetal factors with daughter breast cancer in the CHDS, 
predicted from proportional hazards model simultaneously adjusted for all variables. The top 
three factors are maternal characteristics; T2 and T3 refer to the rate of maternal pregnancy 
weight gain in Trimesters 2 and 3, respectively. Ponderal index and SGA are markers of fetal 
growth. The bottom three factors are placental characteristics.
Maternal characteristics were classified as follow: maternal history of breast cancer (yes vs. 
no), race (East-European vs. all other), overweight at pregnancy baseline measure (BMI > 
25 kg/m2 vs. other), and week of gestation (continuous). Ponderal index was calculated as 
[birthweight (g) / birth length (cm3)]*100 and represented as a 4-category ordinal variable 
coded at quartile medians: 2.14, 2.35, 2.51 and 2.75 respectively for quartiles 1-4. The 
hazard ratio shown is for an increment of one unit. Small for gestational age was defined as 
the lowest decile of the birth-weight-for gestation standardized score vs. all other. High 
trimester-specific rates of maternal weight gain were represented as the 4th quartile of 
weight gain for each trimester vs. all lower quartiles. High 2nd trimester rate of weight gain 
was equivalent to > 1.1690 pounds per week and high 3rd trimester rate of weight gain was 
equal to>0.9996 pounds per week. High placental volume was represented as a dichotomous 
variable,>360 cm3 (above the median) vs.<360 cm3 (at or below the median). Fibrin 
deposition was defined as the presence of maternal floor infarction and/or massive or diffuse 
and patchy subchorionic fibrin vs. absence. Hemorrhage was classified as observed vs. not 
observed.
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